The Serine Protease HtrA1 Specifically Interacts and Degrades the Tuberous Sclerosis Complex 2 Protein

被引:43
作者
Campioni, Mara [1 ]
Severino, Anna [5 ]
Manente, Lucrezia [2 ]
Tuduce, Ioana L. [1 ]
Toldo, Stefano [5 ]
Caraglia, Michele [1 ]
Crispi, Stefania [3 ]
Ehrmann, Michael [6 ]
He, Xiaoping [7 ]
Maguire, Jacie [7 ]
De Falco, Maria [4 ]
De Luca, Antonio [2 ]
Shridhar, Viji [7 ]
Baldi, Alfonso [1 ]
机构
[1] Univ Naples 2, Sect Pathol, Dept Biochem, I-80138 Naples, Italy
[2] Univ Naples 2, Dept Med & Publ Hlth, I-80138 Naples, Italy
[3] CNR, Human Mol Genet Lab, Inst Genet & Biophys, I-80125 Naples, Italy
[4] Univ Naples Federico II, Dept Evolut & Comparat Biol, Naples, Italy
[5] Univ Cattolica Sacro Cuore, Inst Cardiol, Rome, Italy
[6] Univ Duisburg Essen, Ctr Med Biotechnol, Essen, Germany
[7] Mayo Clin, Coll Med, Dept Expt Pathol, Rochester, MN USA
关键词
MAMMALIAN TARGET; MACULAR DEGENERATION; KINASE-ACTIVITY; MESSENGER-RNA; UP-REGULATION; GENE-PRODUCT; PDZ DOMAIN; TSC1; GENE; GROWTH; EXPRESSION;
D O I
10.1158/1541-7786.MCR-09-0473
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Hamartin and tuberin are products of the tumor suppressor genes TSC1 and TSC2, respectively. Mutations affecting either gene result in the tuberous sclerosis syndrome, a neurologic genetic disorder characterized by the formation of multiple benign tumors or hamartomas. In this study, we report the identification of TSC2, but not TSC1, as a substrate of HtrA1, a member of the human HtrA family proteins of serine proteases. We show the direct interaction and colocalization in the cytoplasm of HtrA1 and TSC2 and that HtrA1 cleaves TSC2 both in vitro and in vivo. Finally, we show that alterations in HtrA1 expression cause modifications in phosphorylation status of two downstream targets of TSC2: 4E-BP1 and S6K. Our data suggest that, under particular physiologic or pathologic conditions, HtrA1 degrades TSC2 and activates the downstream targets. Considering that HtrA1 levels are significantly increased during embryogenesis, we speculate that one of the targets of HtrA1 activity during fetal development is the TSC2-TSC1 pathway. Mol Cancer Res; 8(9); 1248-60. (C)2010 AACR.
引用
收藏
页码:1248 / 1260
页数:13
相关论文
共 57 条
[1]
Insulin and amino-acid regulation of mTOR signaling and kinase activity through the Rheb GTPase [J].
Avruch, J. ;
Hara, K. ;
Lin, Y. ;
Liu, M. ;
Long, X. ;
Ortiz-Vega, S. ;
Yonezawa, K. .
ONCOGENE, 2006, 25 (48) :6361-6372
[2]
The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells [J].
Baldi, A ;
De Luca, A ;
Morini, M ;
Battista, T ;
Felsani, A ;
Baldi, F ;
Catricalà, C ;
Amantea, A ;
Noonan, DM ;
Albini, A ;
Natali, PG ;
Lombardi, D ;
Paggi, MG .
ONCOGENE, 2002, 21 (43) :6684-6688
[3]
The serine protease HtrA1 is a novel prognostic factor for human mesothelioma [J].
Baldi, Alfonso ;
Mottolese, Marcella ;
Vincenzi, Bruno ;
Campioni, Mara ;
Mellone, Pasquale ;
Di Marino, Mariapia ;
di Crescenzo, Vincenzo G. ;
Visca, Paolo ;
Menegozzo, Simona ;
Spugnini, Enrico P. ;
Citro, Gennaro ;
Ceribelli, Anna ;
Mirri, Alessandra ;
Chien, Jereiny ;
Shridhar, Viji ;
Ehrmann, Michael ;
Santini, Mario ;
Facciolo, Francesco .
PHARMACOGENOMICS, 2008, 9 (08) :1069-1077
[4]
The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination [J].
Benvenuto, G ;
Li, SW ;
Brown, SJ ;
Braverman, R ;
Vass, WC ;
Cheadle, JP ;
Halley, DJJ ;
Sampson, JR ;
Wienecke, R ;
DeClue, JE .
ONCOGENE, 2000, 19 (54) :6306-6316
[5]
Serine proteases HTRA1 and HTRA3 are down-regulated with increasing grades of human endometrial cancer [J].
Bowden, Marissa A. ;
Di Nezza-Cossens, Lisa A. ;
Jobling, Tom ;
Salamonsen, Lois A. ;
Nie, Guiying .
GYNECOLOGIC ONCOLOGY, 2006, 103 (01) :253-260
[6]
Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning [J].
Cai, SL ;
Tee, AR ;
Short, JD ;
Bergeron, JM ;
Kim, J ;
Shen, JJ ;
Guo, RF ;
Johnson, CL ;
Kiguchi, K ;
Walker, CL .
JOURNAL OF CELL BIOLOGY, 2006, 173 (02) :279-289
[7]
HtrA1: a novel regulator of physiological and pathological matrix mineralization? [J].
Canfield, A. E. ;
Hadfield, K. D. ;
Rock, C. F. ;
Wylie, E. C. ;
Wilkinson, F. L. .
BIOCHEMICAL SOCIETY TRANSACTIONS, 2007, 35 :669-671
[8]
Molecular genetic advances in tuberous sclerosis [J].
Cheadle, JP ;
Reeve, MP ;
Sampson, JR ;
Kwiatkowski, DJ .
HUMAN GENETICS, 2000, 107 (02) :97-114
[9]
A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer [J].
Chien, J ;
Staub, J ;
Hu, SI ;
Erickson-Johnson, MR ;
Couch, FJ ;
Smith, DI ;
Crowl, RM ;
Kaufmann, SH ;
Shridhar, V .
ONCOGENE, 2004, 23 (08) :1636-1644
[10]
HtrA Serine Proteases as Potential Therapeutic Targets in Cancer [J].
Chien, Jeremy ;
Campioni, Mara ;
Shridhar, Viji ;
Baldi, Alfonso .
CURRENT CANCER DRUG TARGETS, 2009, 9 (04) :451-468